On 30 November 2022 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation:
Recommendation No. 111/2022 of 30 November 2022. of the President of the Agency for Health Technology Assessment and Tariff System on the appropriateness of qualifying a healthcare benefit: “Embolisation of intracranial aneurysms with an intracranial aneurysm embolisation device (flow disruptor)” as a guaranteed hospital treatment healthcare service.